-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
At the competition, Xu Minxu, deputy director of the Science and Technology and Economic Commission of Shanghai Pudong New Area, said: “Shanghai has always focused on improving the ability to innovate and source
The Boehringer Ingelheim Innovation Competition is the first biomedical innovation competition hosted by a multinational pharmaceutical company in China.
In the 2021 Boehringer Ingelheim Innovation Competition, a total of 12 companies will be finalists.
In the competition, Yufang Bio-Bio put forward unique insights and research on the problem of myocardial regeneration in the field of gene therapy.
In addition, three start-up companies, Yufang Biology, Ruiwei Microbe, and Wei Silcom, won the most industry attention award in the innovation competition
The judges of this competition included Dr.
Regarding the innovation competition that ended successfully this year, Dr.
Mr.
The champion company of this innovation competition will get the right to use the independent laboratory and the 4-person office in the Boehringer Ingelheim-ATLATL Joint Innovation Laboratory for one year free of charge
It is worth mentioning that in March this year, the first biotech start-up company invested by Boehringer Ingelheim Venture Fund in China was one of the champion companies of the 2020 Boehringer Ingelheim Innovation Competition, Delonix Bioworks (Shanghai Yuguan Biotech Co.
